SELLAS Life Sciences Group, Inc.
Galinpepimut-S (GPS)
Acute Myeloid Leukemia (AML)
Resolved
7days ago
Phase 3 readout · Jun 30, 2026
What's at stake
Phase 3 trial results for Galinpepimut-S (GPS) in Acute Myeloid Leukemia (AML) are due Jun 30, 2026. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 12h ago
“Reaching the required pre-specified 80th event (death) will trigger the customary database lock, blinded data review procedures prior to statistical analysis, unblinding, and disclosure of topline results.”